Total Payments
$79,398
2024 Payments
$24,875
Companies
20
Transactions
119
Medicare Patients
1,096
Medicare Billing
$119,094
Payment Breakdown by Category
Consulting$65,478 (82.5%)
Food & Beverage$6,096 (7.7%)
Other$4,650 (5.9%)
Travel$3,114 (3.9%)
Education$59.99 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $65,478 | 26 | 82.5% |
| Food and Beverage | $6,096 | 76 | 7.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,650 | 3 | 5.9% |
| Travel and Lodging | $3,114 | 13 | 3.9% |
| Education | $59.99 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $27,264 | 16 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $9,047 | 17 | $0 (2024) |
| Astellas Pharma US Inc | $8,731 | 11 | $0 (2024) |
| PFIZER INC. | $7,263 | 12 | $0 (2024) |
| Janssen Research & Development, LLC | $5,685 | 9 | $0 (2024) |
| Astellas Pharma Global Development | $4,360 | 2 | $0 (2024) |
| Daiichi Sankyo Inc. | $3,846 | 4 | $0 (2024) |
| GlaxoSmithKline, LLC. | $3,361 | 7 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,615 | 5 | $0 (2022) |
| Bayer Healthcare Pharmaceuticals Inc. | $2,163 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,875 | 34 | Astellas Pharma US Inc ($7,770) |
| 2023 | $14,250 | 22 | PFIZER INC. ($4,491) |
| 2022 | $9,121 | 9 | GENZYME CORPORATION ($5,394) |
| 2021 | $2,164 | 2 | Daiichi Sankyo Inc. ($2,096) |
| 2020 | $3,566 | 8 | AstraZeneca Pharmaceuticals LP ($2,398) |
| 2019 | $824.04 | 8 | GENZYME CORPORATION ($460.06) |
| 2018 | $6,475 | 16 | E.R. Squibb & Sons, L.L.C. ($4,918) |
| 2017 | $18,123 | 20 | GENZYME CORPORATION ($17,283) |
All Payment Transactions
119 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/25/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 12/16/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $817.50 | General |
| Category: Oncology | ||||||
| 10/11/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Consulting Fee | Cash or cash equivalent | $6,600.00 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $808.66 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $70.76 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $61.04 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Oncology | ||||||
| 07/17/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,645.00 | General |
| 07/15/2024 | PFIZER INC. | TALZENNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,450.00 | General |
| Category: ONCOLOGY | ||||||
| 06/24/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 06/22/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $28.74 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 06/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Consulting Fee | Cash or cash equivalent | $2,163.00 | General |
| Category: Oncology | ||||||
| 06/01/2024 | MACROGENICS, INC. | MARGENZA (Drug) | Food and Beverage | In-kind items and services | $65.14 | General |
| Category: Oncology | ||||||
| 05/31/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $109.11 | General |
| 05/31/2024 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $64.83 | General |
| 05/31/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $55.29 | General |
| 05/31/2024 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 05/16/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $576.43 | General |
| 05/08/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 05/02/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 04/27/2024 | Astellas Pharma Europe BV | Xtandi (Drug) | Food and Beverage | In-kind items and services | $71.55 | General |
| Category: Oncology | ||||||
| 04/26/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $111.44 | General |
| Category: ONCOLOGY | ||||||
| 04/12/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $136.08 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 267 | 359 | $134,075 | $31,408 |
| 2022 | 6 | 312 | 419 | $140,668 | $35,366 |
| 2021 | 8 | 274 | 397 | $105,041 | $30,786 |
| 2020 | 6 | 243 | 328 | $90,221 | $21,535 |
Total Patients
1,096
Total Services
1,503
Medicare Billing
$119,094
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 81 | 128 | $68,515 | $13,803 | 20.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 88 | 126 | $33,432 | $9,534 | 28.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 37 | 37 | $21,110 | $5,100 | 24.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 50 | 56 | $9,578 | $2,713 | 28.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 11 | 12 | $1,440 | $258.39 | 17.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 121 | 180 | $45,895 | $12,691 | 27.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 63 | 99 | $50,907 | $11,458 | 22.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 57 | 57 | $31,279 | $7,695 | 24.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 40 | 49 | $8,029 | $2,344 | 29.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 13 | 13 | $2,113 | $713.29 | 33.8% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2022 | 18 | 21 | $2,445 | $464.09 | 19.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 109 | 211 | $51,656 | $16,430 | 31.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 29 | 40 | $19,992 | $4,730 | 23.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 23 | 23 | $12,445 | $3,501 | 28.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 41 | 47 | $7,440 | $2,499 | 33.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 15 | 15 | $6,105 | $1,641 | 26.9% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2021 | 27 | 28 | $3,148 | $773.50 | 24.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 11 | 12 | $1,884 | $616.11 | 32.7% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 19 | 21 | $2,371 | $595.00 | 25.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 80 | 142 | $33,716 | $8,730 | 25.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 45 | 45 | $24,858 | $5,894 | 23.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 60 | 70 | $10,686 | $2,670 | 25.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 24 | 28 | $13,352 | $2,306 | 17.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 17 | $4,811 | $1,471 | 30.6% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Facility | 2020 | 22 | 26 | $2,798 | $464.20 | 16.6% |
About Ana Aparicio
Ana Aparicio is a Hematology & Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720033657.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ana Aparicio has received a total of $79,398 in payments from pharmaceutical and medical device companies, with $24,875 received in 2024. These payments were reported across 119 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($65,478).
As a Medicare-enrolled provider, Aparicio has provided services to 1,096 Medicare beneficiaries, totaling 1,503 services with total Medicare billing of $119,094. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Houston, TX
- Active Since 05/22/2006
- Last Updated 07/27/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1720033657
Products in Payments
- JEVTANA (Drug) $17,798
- Xtandi (Drug) $12,202
- NO PRODUCT DISCUSSED (Drug) $9,835
- TALZENNA (Drug) $6,450
- LYNPARZA (Drug) $2,398
- ERLEADA (Drug) $2,292
- Nubeqa (Drug) $2,163
- XTANDI (Drug) $505.36
- Erleada (Drug) $490.10
- PROVENGE (Drug) $349.82
- Blincyto (Biological) $275.00
- OPDIVO (Biological) $214.30
- LIBTAYO (Biological) $133.09
- TAXOTERE (Drug) $118.45
- CABOMETYX (Drug) $107.26
- ZYTIGA (Drug) $96.85
- MARGENZA (Drug) $65.14
- Kyprolis (Drug) $50.87
- FOTIVDA (Drug) $19.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Houston
Devesh Pandya, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
Elias Jabbour, M.d, M.D
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Naval Daver, Mbbs, MBBS
Hematology & Oncology — Payments: $983,097
Hematology & Oncology $983,097
Jorge Cortes-Franco, M.d, M.D
Hematology & Oncology — Payments: $927,016
Hematology & Oncology $927,016
Dr. Luis Camacho, M.d., Mph, M.D., MPH
Hematology & Oncology — Payments: $491,819
Hematology & Oncology $491,819
Christopher Flowers, M.d, M.D
Hematology & Oncology — Payments: $320,001
Hematology & Oncology $320,001